David Gomez-Pastrana

Dr. David Gomez-Pastrana

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DGDavid Gomez-Pastrana
David Gomez-Pastrana
RTRafael Torronteras
Rafael Torronteras
PCPilar Caro
Pilar Caro
MAMaria Luisa Anguita
Maria Luisa Anguita
ALAntonio María López-Barrio
Antonio María López-Barrio
JNJuan Navarro
Juan Navarro
A total of 251 clinical specimens (235 gastric aspirates and 16 bronchoalveolar lavages) from 88 children were prospectively tested in a blinded manner for the presence of Mycobacterium tuberculosis complex, by use of the Amplicor M. tuberculosis test and by means of in-house polymerase chain reaction (PCR). The results were compared with those obtained by conventional culture and by direct microscopy. All of the children underwent extended follow-up to verify or exclude the clinical diagnosis of tuberculosis. The results of the different tests, when compared to the final clinical diagnosis, were a sensitivity of 60% and a specificity of 96.8% for in-house PCR, 44% and 93.7% respectively for the Amplicor test, 44% and 100% for mycobacterial culture and 12% and 100% for microscopy. Amplicor tests presented false-positive findings in children without tuberculous infection. We conclude that both in-house PCR and the Amplicor test are rapid methods that can be helpful for difficult or urgent diagnosis of tuberculosis in children. However, efforts should be aimed toward improvement of the sensitivity and specificity of an easy-to-use PCR kit.

26 October 1999 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DGDavid Gomez-Pastrana
David Gomez-Pastrana
RTRafael Torronteras
Rafael Torronteras
PCPilar Caro
Pilar Caro
MAMaria Luisa Anguita
Maria Luisa Anguita
JNJuan Navarro
Juan Navarro

30 September 2010 in Anales de Pediatría
Verified
Journal Article
Closed access
DMD. Moreno-Pérez
D. Moreno-Pérez
AMA. Andrés Martín
A. Andrés Martín
NGN. Altet Gómez
N. Altet Gómez
FBFernando Baquero-Artigao
Fernando Baquero-Artigao
AMA. Escribano Montaner
A. Escribano Montaner
MSM.J. Ruiz Serrano
M.J. Ruiz Serrano

1 January 2018 in Anales de Pediatría
Verified
Journal Article
Open access
MPMaría José Mellado Peña
María José Mellado Peña
BGBegoña Santiago García
Begoña Santiago García
FBFernando Baquero-Artigao
Fernando Baquero-Artigao
DPDavid Moreno Pérez
David Moreno Pérez
RPRoi Piñeiro Pérez
Roi Piñeiro Pérez
AJAntoni Noguera Julian
Antoni Noguera Julian
Tuberculosis (TB) is the most important infectious disease all over the world, with a high morbidity and mortality. Pediatric tuberculosis has been a neglected epidemic, due to the difficulties in assessing its global impact, reduced incidence and lower infectivity compared to adults. In 2015, the WHO reported 1 million cases of paediatric TB and 169,000 deaths. In Europe, the emergence of MDR TB is a major concern, representing 16% of the new diagnosis in Eastern Europe. In 2014, it was estimated that about 219,000 children were infected by MDR-TB-strains in Europe, and 2,120 developed the disease. Spain is the Western European country with more paediatric cases, with an incidence 4.3/100,000 inhabitants in 2014. Paediatric tuberculosis mortality in Spain is rare, but extra-pulmonary disease is associated with significant complications. The prevalence of paediatric drug resistant TB in Spain is over 4%, higher than the estimated incidence in adult population, representing mayor difficulties for therapeutic intervention. These data reveal that paediatric TB is still a Public Health priority in our country. The difficulties in diagnosis and the lack of optimal paediatric drug formulations are the major challenges for controlling the childhood's tuberculosis epidemic. A group of national paeditric TB experts has reviewed the international guidelines and the most recent evidences, and has established new recommendations for the management of paediatric TB contacts, latent infection and active TB disease, especially focused in drug resistant cases. This document replaces the former national guidelines from the Spanish Society for Pediatric Infectios Diseases, although the prior recommendations on the diagnosis remain valid.

1 September 2002 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
DGDavid Gomez-Pastrana
David Gomez-Pastrana

1 September 2022 in Thorax
Verified
Journal Article
Closed access
PDF file
DADavid Aguilera-Alonso
David Aguilera-Alonso
GSGonzalo Solis-Garcia
Gonzalo Solis-Garcia
ANAntoni Noguera-Julian
Antoni Noguera-Julian
Juliá GonzalezJuliá Gonzalez
Juliá Gonzalez
ACAngely Román Cobeña
Angely Román Cobeña
BGBegoña Santiago García
Begoña Santiago García
Introduction Childhood pulmonary tuberculosis (TB) remains a diagnostic challenge. This study aimed to evaluate the performance of Xpert Ultra for the diagnosis of pulmonary TB in children in a low TB prevalence setting. Methods Prospective, multicentre, diagnostic accuracy study. Children with clinical or radiological suspicion of pulmonary TB were recruited at 11 paediatric units in Spain. Up to three gastric or sputum specimens were taken on 3 consecutive days, and analysed by Xpert MTB/RIF, Xpert Ultra and culture in parallel. Results 86 children were included (median age 4.9 years, IQR 2.0–10.0; 51.2% male). The final diagnosis was pulmonary TB in 75 patients (87.2%); 33 (44.0%) were microbiologically confirmed. A total of 219 specimens, comprising gastric aspirates (n=194; 88.6%) and sputum specimens (n=25; 11.4%), were analysed. Using culture as reference standard and comparing individual specimens, the sensitivity was 37.8% (14/37) for Xpert MTB/RIF and 81.1% (30/37) for Xpert Ultra (p<0.001); specificity was 98.4% (179/182) and 93.4% (170/182), respectively (p=0.02). In the per-patient analysis, considering positive results on any specimen, the sensitivity was 42.9% (9/21) for Xpert MTB/RIF and 81.0% for Xpert Ultra (17/21, p=0.01); specificity was 96.9% (63/65) and 87.7% (57/65, p=0.07), respectively. Conclusions In children with pulmonary TB in a low burden setting, Xpert Ultra has significantly higher sensitivity than the previous generation of Xpert assay and only marginally lower specificity. Therefore, in children undergoing evaluation for suspected pulmonary TB, Xpert Ultra should be used in preference to Xpert MTB/RIF whenever possible.